Premium
The Effects of Eprosartan, an Angiotensin II AT 1 Receptor Antagonist, on Uric Acid Excretion in Patients with Mild to Moderate Essential Hypertension
Author(s) -
Ilson Bernard E.,
Martin David E.,
Boike Steven C.,
Jorkasky Diane K.
Publication year - 1998
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1998.tb04450.x
Subject(s) - uric acid , excretion , chemistry , medicine , angiotensin ii , endocrinology , placebo , creatinine , angiotensin ii receptor antagonist , urine , crossover study , pharmacology , angiotensin receptor , blood pressure , alternative medicine , pathology
The effects of antihypertensive agents, including angiotensin II receptor antagonists, on urine uric acid excretion may have important clinical consequences. Therefore, the effects of single and repeated doses of eprosartan on uric acid excretion were evaluated in 57 male patients with mild‐to‐moderate essential hypertension in a double‐blind, randomized, placebo‐controlled, repeated dose, dose‐rising, two‐period, period‐balanced, crossover study conducted in two parts. In part 1 (n = 33), the effects of eprosartan dose regimens of of 50 mg, 100 mg, and 350 mg once daily and 150 mg every 12 hours on uric acid excretion were assessed. In part 2 (n = 24), the effects of eprosartan dose regimens of 600 mg, 800 mg, and 1,200 mg once daily on uric acid excretion were assessed. Eprosartan was well tolerated. There were no appreciable changes from predose values in fractional excretion of uric acid (FE ua ), urine uric acid excretion, urine uric acid to creatinine (U ua /U cr ) ratios, or serum uric acid concentrations after single or repeated doses of eprosartan. Mean U ua /U cr ratios for eprosartan doses of 50 mg, 100 mg, or 350 mg daily or 150 mg every 12 hours were comparable to those for placebo. Mean FE ua values and U ua /U cr ratios for eprosartan doses of 600 mg, 800 mg, or 1,200 mg daily also were comparable to those for placebo. Single and repeated oral doses of eprosartan ranging from 50 mg to 1,200 mg daily had no effect on serum uric acid concentrations or urine uric acid excretion in patients with mild‐to‐moderate essential hypertension.